Bruker Launches New timsTOF-based MALDI PharmaPulse® Solution for Label-free HTS in Drug Discovery
February 07 2022 - 6:00AM
Business Wire
timsTOF MALDI PharmaPulse® (timsTOF MPP) for
Unprecedented High-Throughput Screening (HTS) information content
and throughput
- Innovative timsTOF platform combined with extreme MALDI
PharmaPulse speed and robustness for unbiased, deep HTS and uHTS
(ultra-high-throughput screening)
- Trapped Ion Mobility Spectrometry (TIMS): Exploiting ion
mobility separation as a new dimension in HTS combined with high
resolution QTOF-MS
- Enabling new insights into molecular interactions in
label-free HTS and uHTS in drug discovery
- Accelerating drug molecule design by ultra-fast,
information-rich CCS-enabled synthesis screening in support of HTE
chemistry
At the SLAS2022 International Conference and Exhibition, Bruker
Corporation (Nasdaq: BRKR) today announced the launch of its
timsTOF MALDI PharmaPulse® (timsTOF MPP) system, a groundbreaking
new high-end solution for unbiased, deep HTS and uHTS based on
label-free mass spectrometry.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220207005153/en/
timsTOF MALDI PharmaPulse (Graphic:
Business Wire)
The new timsTOF® MPP is now the flagship of Bruker´s MALDI
PharmaPulse product family which became a game changer in the HTS
market with the launch of the rapifleX MPP, a MALDI-TOF-based
label-free uHTS solution, in 2017.
The timsTOF MPP features the extreme speed and proven robustness
of MALDI and, for the first time ever in HTS, takes advantage of
Bruker´s innovative Trapped Ion Mobility Spectrometry (TIMS)
technology. TIMS enables rapid gas-phase separation of isobars, and
even isomers, by exploiting the molecular collisional
cross-section. This, in combination with routine 50,000 mass
resolution at full speed with QTOF-MS detection enables
revolutionary levels of assay specificity at HTS speed.
The timsTOF MPP features a dual MALDI / ESI ion source with
industry-leading 10 kHz smartbeam™ 3D laser to enable uHTS
compatible speed and throughput, and is available with the unique
MALDI-2 option for an expanded chemical space.
As part of the timsTOF MPP solution, the new MALDI PharmaPulse®
2023 software supports a broad range of HTS applications for drug
discovery. Its automation interface allows for timsTOF MPP
integration in high throughput environments and works in concert
with common scheduling software packages from various vendors.
Furthermore, MPP 2023 features seamless transfer of data and
results to downstream analysis software, e.g., to Genedata
Screener®.
Dr. Meike Hamester, Director of Label-free BioPharma
Technologies at Bruker Daltonics, stated: “The timsTOF MPP is a
major step towards higher efficiency in drug development as it
reduces the need for orthogonal assays and technologies by its
significantly higher HTS information content and, thus, further
lowering of the false discovery rate (FDR). The high specificity of
TIMS in combination with high resolution QTOF-MS detection is a
great advantage for a broad variety of screening workflows such as
binding assays, phenotype screening and biochemical and cell-based
mechanistic assays. Furthermore, timsTOF MPP offers great potential
for CCS-enabled near real-time synthesis screening in
high-throughput experimentation (HTE) chemistry, paving the way to
newly designed drug molecules. Bruker´s recently introduced laser
based post-ionization technology (MALDI-2), can serve as a highly
capable tool to expand the accessible analyte space adding to the
versatility of this innovative platform.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220207005153/en/
Media Contact Dr. Petra
Scheffer Director Marketing Solutions T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com Investor
Contact: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Daltonics Marketing
Communications Bruker Corporation T: +1 (978) 663-3660 x1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024